To validate the ADCC and CDC assays, we measured SwIAV-specific ADCC activity in the serum of pigs previously immunized with four different nanovaccine formulations and a commercial swine flu vaccine, while in influenza antibody-free pigs vaccinated with two types of nanovaccines containing a STING adjuvant, we observed relatively low levels of ADCC activity than the commercial SwIAV vaccine (Figure 3(i) A, B). The gene discussed is STING1; the disease is influenza.